Dey B, Sykes M, Spitzer T R
Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA.
Medicine (Baltimore). 1998 Sep;77(5):355-69. doi: 10.1097/00005792-199809000-00005.
In this review we examine the clinical outcomes of patients who have received both bone marrow transplantation (BMT) and solid organ transplantation (SOT) and discuss the possible immunologic consequences of the dual transplants. We collected cases through a comprehensive literature search (MEDLINE database, English literature only) covering the years 1990 through 1997 and correspondence with the International Bone Marrow Transplant Registry. Our study selected case reports of patients who have undergone both bone marrow and solid organ transplants; cases in which bone marrow transplantation was undertaken as an adjunct ot induce or augment donor-specific tolerance in a recipient to the transplanted organ were excluded. Clinical characteristics included patient's demographic information, underlying disorders for each transplant, source of donor organ or tissue, time between transplants, and immunosuppressive regimens used to prevent graft-versus-host disease (GVHD) or graft rejection. Clinical outcomes included patient survival, complications of transplantation, and donor-specific tolerance that was experienced in many cases. Twenty-one cases of SOT after BMT and 7 cases of BMT after SOT were reviewed. Solid organ transplantations included lung, liver, cardiac, and kidney for a variety of BMT-related complications including GVHD, hepatic veno-occlusive disease, chronic renal failure, end-stage pulmonary disease, and severe cardiomyopathy. Bone marrow transplants were performed following SOT for aplastic anemia and hematologic malignancies. Clinical outcomes for patients who received both BMT and SOT were variable and depended on transplant indication and degree of histocompatibility. Prior bone marrow transplantation may tolerize for a subsequent organ transplant from the same donor. Conversely, severe GVHD may follow BMT from human leukocyte antigen (HLA)-matched donors following SOT. The favorable survival in this high-risk group of patients may represent a literature review bias (that is, an undetermined number of unsuccessful cases may not have been reported). Nonetheless, dual transplantation is clearly feasible in selected cases.
在本综述中,我们研究了接受骨髓移植(BMT)和实体器官移植(SOT)的患者的临床结局,并讨论了双重移植可能产生的免疫后果。我们通过全面的文献检索(仅检索MEDLINE数据库中的英文文献)收集了1990年至1997年的病例,并与国际骨髓移植登记处进行了通信联系。我们的研究选择了接受过骨髓和实体器官移植的患者的病例报告;排除了将骨髓移植作为辅助手段以诱导或增强受者对移植器官的供体特异性耐受性的病例。临床特征包括患者的人口统计学信息、每次移植的基础疾病、供体器官或组织的来源、两次移植之间的时间间隔以及用于预防移植物抗宿主病(GVHD)或移植排斥的免疫抑制方案。临床结局包括患者生存率、移植并发症以及许多病例中出现的供体特异性耐受性。回顾了21例BMT后进行SOT的病例和7例SOT后进行BMT的病例。实体器官移植包括肺、肝、心脏和肾脏移植,用于治疗各种与BMT相关的并发症,包括GVHD、肝静脉闭塞病、慢性肾衰竭、终末期肺病和严重心肌病。SOT后因再生障碍性贫血和血液系统恶性肿瘤进行了骨髓移植。接受BMT和SOT的患者的临床结局各不相同,取决于移植指征和组织相容性程度。先前的骨髓移植可能会使受者对来自同一供体的后续器官移植产生耐受性。相反地,SOT后接受来自人类白细胞抗原(HLA)匹配供体的BMT可能会发生严重的GVHD。这一高危患者群体的良好生存率可能代表了文献综述的偏差(即可能未报告数量不确定的未成功病例)。尽管如此,在特定病例中双重移植显然是可行的。